An Optimal Scheme for Memory Management in Fault-tolerant Real-time System

探讨如何把抢占门限应用于具有优先级提升和内存受限的实时系统,并进一步研究了互不抢占组内,linux平台上基于增量检测点的内存备份/恢复的方法及原型系统的实现。原型系统采用了可扩展的链接方式作为检测点文件格式,使得数据更加紧凑有序;在内存的备份操作上,提出了“影子脏位”算法来识别两检测点之间有无被改变的部分。原型实验验证了所提出方法的有效性。After analyzing how to apply preemption-threshold-scheduling into real-time systems among which the recoveries of safety tasks may be executed at higher priority levels and the sizes of memories are limited,we research realization methods about memory backuprecovery on the Linux platform based on increment checkpoints for no-preemption task groups.At last,taking the microcomputer interlocking simulation system as an example,prototype experiment of memory backup/recovery has been done on the Linux platform in the lab.Our prototype experiment takes an extendable checkpoint file layout to make data in a file compact.And with regard of memory backup operation,by using a″showdown of dirty-bit″ algorithm to identify the difference between two checkpoints,it implements an increment checkpoint to improve system performance.This experiment has proved the validity of proposed methods.广东省自然科学基金(06029667

藏文短语及其嵌套短语的提取

本文提出一种自动提取藏文短语及其嵌套短语搭配的算法,它通过采用基于统计长短语内词语之间的触发共现和基于句法特征规则相结合的处理策略,利用数据挖掘中的Apriori算法和FTP Tree数据存储结构,克服了N-gram统计语言模型在藏文短语搭配提取中没有考虑语言本身结构特性的缺陷,实验结果表明,短语提取的准确率和召回率都有很大的提高.中国中文信息学

西江肇庆江段鱼类早期资源时空分布特征研究

2006年5～7月对西江肇庆江段鱼苗的时空分布进行了研究,结果表明:5月17日及6月1日前后该江段有苗汛发生,鱼苗密度平均值为0.83尾/m3,最大值为7.9尾/m3;鱼苗密度昼夜分布有显著性差异(n=26,P<0.01),夜间的密度比白天的高;鱼苗的种类在昼夜分布上也有明显差异,四大家鱼鱼苗的分布主要集中于夜间;鱼苗的分布具空间差异性,近岸的鱼苗密度高于江中央的

青皮塘产卵场广东鲂繁殖群体的水声学探测

2006年4—5月利用Simrad EY60型分束回声探测仪对青皮塘广东鲂产卵场的繁殖群体进行定点横向探测及航行垂直探测。在人工标定及同步渔获物统计的基础上,对广东鲂的回声信号进行了判别。结果表明:广东鲂在青皮塘产卵场有明显的聚集、逗留行为,其游动速度(均值0.24m·s-1)低于其他鱼类(均值0.49m·s-1);广东鲂繁殖个体目标强度的范围为-33.8~-52.3dB,均值为-42.2dB;4月27日—5月1日,广东鲂在青皮塘的聚群过程约经历了4d;初步估算5月1日青皮塘产卵场广东鲂繁殖群体数量为9

Three-arm annular inspection tour robot mechanism

本实用新型涉及移动机器人机构，具体地说是一种三臂环形巡检机器人机构，包括前、下、后轮爪机构，前、下、后摇臂机构和中心轮，前、下、后摇臂机构的一端通过转动机构与中心轮连接，另一端分别与前、下、后摆臂的一端通过前、下、后俯仰机构转动连接，前、下、后摆臂的另一端通过回转机构与前、下、后轮爪机构转动连接，前、下、后轮爪机构的另一端设有在输电线上行走的行走机构及夹紧输电线的夹紧机构；前、下、后俯仰机构结构相同，包括转动副及驱动电机；前、下、后回转机构结构相同，包括转动副及驱动电机。本实用新型具有能够跨越引流线等复杂的障碍物能力，可适应地线、导线等多种线路环境，具有结构简单，越障能力强，应用范围广等优点

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials